Published in Arch Intern Med on May 01, 1986
Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ (2009) 4.38
Molecular analysis of the contribution of the capsular polysaccharide and the lipopolysaccharide O side chain to the virulence of Klebsiella pneumoniae in a murine model of pneumonia. Infect Immun (2002) 1.88
Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. Can J Infect Dis Med Microbiol (2008) 1.68
Role of the htrA gene in Klebsiella pneumoniae virulence. Infect Immun (2002) 1.25
Host and microbiota factors that control Klebsiella pneumoniae mucosal colonization in mice. Microbes Infect (2008) 1.07
Role of lung epithelial cells in defense against Klebsiella pneumoniae pneumonia. Infect Immun (2002) 1.05
Monoclonal antibody against Klebsiella capsular polysaccharide reduces severity and hematogenic spread of experimental Klebsiella pneumoniae pneumonia. Infect Immun (1992) 1.04
Identification of Klebsiella pneumoniae genes uniquely expressed in a strain virulent using a murine model of bacterial pneumonia. Microb Pathog (2007) 1.00
Epidemiology of infection in ICUs. Intensive Care Med (1994) 0.97
Roles of capsule and lipopolysaccharide O antigen in interactions of human monocyte-derived dendritic cells and Klebsiella pneumoniae. Infect Immun (2009) 0.95
Oropharyngeal flora and chest infection after upper abdominal surgery. Thorax (1991) 0.92
Adenosine A(2B) receptor deficiency promotes host defenses against gram-negative bacterial pneumonia. Am J Respir Crit Care Med (2012) 0.91
Klebsiella pneumoniae triggers a cytotoxic effect on airway epithelial cells. BMC Microbiol (2009) 0.90
Nosocomial lower respiratory tract infections: prevalence and risk factors in 14 Greek hospitals. Eur J Clin Microbiol Infect Dis (2004) 0.90
New and future antibiotics in the treatment of acute respiratory tract infections. Thorax (1995) 0.85
Nosocomial pneumonia: epidemiology and infection control. Intensive Care Med (1992) 0.84
Noncapsulated Klebsiella pneumoniae bearing mannose-containing O antigens is rapidly eradicated from mouse lung and triggers cytokine production by macrophages following opsonization with surfactant protein D. Infect Immun (2005) 0.83
Binding to and opsonophagocytic activity of O-antigen-specific monoclonal antibodies against encapsulated and nonencapsulated Klebsiella pneumoniae serotype O1 strains. Infect Immun (2000) 0.82
Staphylococcus aureus proteases degrade lung surfactant protein A potentially impairing innate immunity of the lung. J Innate Immun (2012) 0.81
Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can J Infect Dis (2000) 0.81
Antibody response to Prevotella spp. in patients with ventilator-associated pneumonia. Clin Diagn Lab Immunol (1996) 0.80
Systemic antibiotic treatment of nosocomial pneumonia. Intensive Care Med (1992) 0.79
Anaerobic Infections of the Lung. Curr Infect Dis Rep (2000) 0.79
Intranasal immunization with a colloid-formulated bacterial extract induces an acute inflammatory response in the lungs and elicits specific immune responses. Infect Immun (2004) 0.78
The relationship between gut-derived bacteria and the development of the multiple organ dysfunction syndrome. J Anat (1996) 0.76
Aminoglycoside therapy: current and prospective uses. Tex Heart Inst J (1990) 0.75
The scope of lower respiratory tract infection. Infection (1991) 0.75
Polymicrobial pneumococcal bacteraemia: a case-control study. Eur J Clin Microbiol Infect Dis (2017) 0.75
Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med (1978) 14.65
Plasmid-controlled colonization factor associated with virulence in Esherichia coli enterotoxigenic for humans. Infect Immun (1975) 14.65
Tularemia as a biological weapon: medical and public health management. JAMA (2001) 13.23
Production of vascular permeability factor by enterotoxigenic Escherichia coli isolated from man. Infect Immun (1973) 9.99
Botulinum toxin as a biological weapon: medical and public health management. JAMA (2001) 9.18
Susceptibility of anaerobes to cefoxitin and other cephalosporins. Antimicrob Agents Chemother (1975) 8.86
In vitro activity of thienamycin. Antimicrob Agents Chemother (1978) 8.76
Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (2000) 8.45
Anaerobic infections. 1. N Engl J Med (1974) 8.02
Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 7.96
Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis (1977) 7.68
Enterotoxigenic Escherichia coli isolated from patients with severe cholera-like disease. J Infect Dis (1971) 7.10
Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 7.06
In vitro activity of LY127935. Antimicrob Agents Chemother (1979) 7.01
Acute undifferentiated human diarrhea in the tropics. I. Alterations in intestinal micrflora. J Clin Invest (1971) 6.23
Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology (1978) 5.91
Toxigenic Escherichia coli: a cause of infantile diarrhea in Chicago. N Engl J Med (1972) 5.45
Cloning and sequencing of the class B beta-lactamase gene (ccrA) from Bacteroides fragilis TAL3636. Antimicrob Agents Chemother (1990) 5.24
Treating diarrhoea. BMJ (1997) 5.22
Travelers' diarrhea and toxigenic Escherichia coli. N Engl J Med (1975) 5.20
Comparison of two toxins produced by Clostridium difficile. Infect Immun (1981) 5.16
Polymyxin B-Induced Release of Low-Molecular-Weight, Heat-Labile Enterotoxin from Escherichia coli. Infect Immun (1974) 4.79
Glanders in a military research microbiologist. N Engl J Med (2001) 4.77
Clostridium difficile colitis: an efficient clinical approach to diagnosis. Ann Intern Med (1995) 4.42
Cytotoxicity assay in antibiotic-associated colitis. J Infect Dis (1979) 4.39
Activity of cefamandole and other cephalosporins against aerobic and anaerobic bacteria. Antimicrob Agents Chemother (1976) 4.07
Identification of enterotoxigenic Escherichia coli and serum antitoxin activity by the vascular permeability factor assay. Infect Immun (1973) 4.07
Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology (1981) 4.04
Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients. Infect Immun (1978) 3.93
Experimental intra-abdominal abscesses in rats: development of an experimental model. Infect Immun (1974) 3.91
In vitro activity of N-formimidoyl thienamycin (MK0787). Antimicrob Agents Chemother (1980) 3.90
Clinical and laboratory observations in Clostridium difficile colitis. Am J Clin Nutr (1980) 3.89
Beta-lactamase-mediated imipenem resistance in Bacteroides fragilis. Antimicrob Agents Chemother (1986) 3.87
Intestinal microflora. Gastroenterology (1971) 3.86
Intestinal flora in health and disease. Gastroenterology (1984) 3.84
Susceptibility of the Bacteroides fragilis group in the United States in 1981. Antimicrob Agents Chemother (1983) 3.83
Quantitative bacteriology of the vaginal flora. J Infect Dis (1977) 3.81
Principles of appropriate antibiotic use for acute pharyngitis in adults: background. Ann Intern Med (2001) 3.75
Studies of intestinal microflora. II. Microorganisms of the small intestine and their relations to oral and fecal flora. Gastroenterology (1967) 3.71
Management of anaerobic infections. Ann Intern Med (1975) 3.62
Metronidazole versus anaerobes. In vitro data and initial clinical observations. Calif Med (1972) 3.62
The capsular polysaccharide of Bacteroides fragilis as a virulence factor: comparison of the pathogenic potential of encapsulated and unencapsulated strains. J Infect Dis (1977) 3.62
Studies of intestinal microflora. I. Effects of diet, age, and periodic sampling on numbers of fecal microorganisms in man. Gastroenterology (1967) 3.60
Rapid diagnosis of anaerobic infections by direct gas-liquid chromatography of clinical speciments. J Clin Invest (1976) 3.34
Anaerobic pleuropulmonary infections. Medicine (Baltimore) (1972) 3.30
Microbial synergy in experimental intra-abdominal abscess. Infect Immun (1976) 3.21
Abdominal trauma, anaerobes, and antibiotics. Surg Gynecol Obstet (1973) 3.18
Anaerobic infections (second of three parts). N Engl J Med (1974) 3.18
Principles of appropriate antibiotic use for acute rhinosinusitis in adults: background. Ann Intern Med (2001) 3.15
Colitis induced by Clostridium difficile. Rev Infect Dis (1980) 3.15
Anaerobic infections (third of three parts). N Engl J Med (1974) 3.13
Bacteroides fragilis resistant to the administration of clindamycin. Am J Med (1976) 3.13
In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob Agents Chemother (1993) 3.13
Intestinal fluid and electrolyte transport in human cholera. J Clin Invest (1970) 3.09
Enzyme immunoassays for detection of Clostridium difficile toxins A and B in fecal specimens. J Infect Dis (1984) 3.07
Treatment of anaerobic infections with lincomycin and clindamycin. N Engl J Med (1972) 3.05
Studies on enterotoxin from Escherichia coli associated with acute diarrhea in man. J Lab Clin Med (1971) 3.03
Antibiotic-associated pseudomembranous colitis. Rev Infect Dis (1980) 3.02
Antigenic analysis of Campylobacter flagellar protein and other proteins. J Clin Microbiol (1985) 2.92
Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet (1978) 2.87
Cultures for Clostridium difficile in stools containing a cytotoxin neutralized by Clostridium sordellii antitoxin. J Clin Microbiol (1979) 2.86
Characterization of pBFTM10, a clindamycin-erythromycin resistance transfer factor from Bacteroides fragilis. J Bacteriol (1982) 2.80
Survival of Lactobacillus species (strain GG) in human gastrointestinal tract. Dig Dis Sci (1992) 2.78
Oxygen tolerance of fresh clinical anaerobic bacteria. J Clin Microbiol (1975) 2.77
Inactivation of cephalosporins by Bacteroides. Antimicrob Agents Chemother (1979) 2.75
Pseudomembranous enterocolitis (antibiotic-related colitis). Adv Intern Med (1977) 2.73
Antimicrobial susceptibilities of 1,292 isolates of the Bacteroides fragilis group in the United States: comparison of 1981 with 1982. Antimicrob Agents Chemother (1984) 2.71
Cefoxitin inactivation by Bacteroides fragilis. Antimicrob Agents Chemother (1983) 2.64
Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology (1980) 2.60
Hormone levels during dietary changes in premenopausal African-American women. J Natl Cancer Inst (1996) 2.59
Effect of preoperative neomycin-erythromycin intestinal preparation on the incidence of infectious complications following colon surgery. Ann Surg (1973) 2.57
Antimicrobial therapy of experimental intraabdominal sepsis. J Infect Dis (1975) 2.56
Stimulation of intestinal adenyl cyclase by Escherichia coli enterotoxin: comparison of strains from an infant and an adult with diarrhea. J Infect Dis (1974) 2.52
Tn4400, a compound transposon isolated from Bacteroides fragilis, functions in Escherichia coli. J Bacteriol (1985) 2.48
Nationwide study of the susceptibility of the Bacteroides fragilis group in the United States. Antimicrob Agents Chemother (1985) 2.47
Anaerobic infections of the lung and pleural space. Am Rev Respir Dis (1974) 2.46
Mechanisms of drug-resistance transfer in Bacteroides fragilis. J Antimicrob Chemother (1981) 2.46
Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation. Antimicrob Agents Chemother (1988) 2.45